Efficacy and safety of obinutuzumab in active lupus nephritis
NEJM, 2025. Epub ahead of print. DOI: 10.1056/NEJMoa2410965
Furie et al. demonstrated that obinutuzumab plus standard therapy significantly improved complete renal response at Wk76 compared with placebo. No unexpected safety signals were identified, though infections and COVID-19-related events were more frequent in the obinutuzumab group.
The study assessed the efficacy and safety of obinutuzumab in patients with active LN receiving standard therapy with mycophenolate mofetil and prednisone. A total of 271 patients were randomised 1:1 to receive obinutuzumab or placebo. The primary endpoint, a complete renal response at Wk76, was achieved in 46.4% of patients receiving obinutuzumab compared to 33.1% in the placebo group.
